Immatics reports Q3 EPS (EUR 0.42) vs (EUR 0.08) vs last year

Reports Q3 revenue EUR 5.187M vs EUR 50.559M last year. “In the last months, we have achieved significant clinical milestones and solidified Immatics (IMTX)’ position as the PRAME leader across two modalities, cell therapies and bispecifics,” said Harpreet Singh, Ph.D., Chief Executive Officer and Co-Founder of Immatics. “With the recent data update and clinical proof-of-concept for our TCR Bispecifics pipeline, we’re entering the next exciting phase of bispecifics development while continuing to advance anzu-cel, our PRAME cell therapy, towards commercialization. At Immatics, our priority is the patients we serve, and every advancement in our clinical pipeline brings us closer to delivering meaningful and durable benefits to them through our innovative TCR-based therapeutics.”